Default company panoramic image

Fedora Pharmaceuticals Inc.

U.S. drug resistance causes +63,000 deaths and costs +$20 billion annually! Fedora's drug reverses resistance. Annual market is +$1 billion.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Edmonton, AB, Canada
  • Currency CAD

Company Summary

Fedora's team have made an important discovery believed to be the first of its kind: A single product that potentiates the activity of antibiotics such as penicillin and restores activity. There is no such drug on the market or in development that possesses the same spectrum as Fedora's. A near virtual team of world recognized industry experts will advance the program to commercialization in as short a time as possible.


  • Default avatar
    Christopher George Micetich
    Founder/President & CEO

  • Default avatar
    Dr. Thomas Parr
    Chief Scientific Officer

  • Default avatar
    Dr. Karen Bush
    S.A.B. Member

  • Default avatar
    Dr. Eric Gordon
    S.A.B. Member